EUVIMEDEUVIMED entdecken
Multizentrische Studie

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

Vincent Jachiet, Olivier Kosmider iD, Maxime Beydon iD, Jérôme Hadjadj, Lin-Pierre Zhao iD, Vincent Grobost iD, Valentin Lacombe, Guillaume Le Guenno iD, Yann Nguyen iD, Jean-Benoît Arlet, Jérémie Dion iD, Maël Heiblig iD und 42 weitere

Blood · 18.09.2025 · 146 (12) · 1450-1461

DOI: 10.1182/blood.2024028133 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Blood, erschienen am 18.09.2025. Verfasst von Vincent Jachiet und 53 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Interne, Hôpital Saint-Antoine, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses, Assistance Publique-Hôpitau…. Hauptthemen laut MEDLINE: Antimetabolites, Antineoplastic, Azacitidine, Myelodysplastic Syndromes, Skin Diseases, Genetic. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a severe monogenic disorder caused by somatic mutations in ubiquitin-like modifier activating enzyme 1 (UBA1), characterized by inflammation, cytopenias, and frequent association with myelodysplastic neoplasms (MDS). Steroid dependence is common, and targeted therapies have demonstrated limited efficacy. Azacitidine (AZA), a hypomethylating agent used in MDS, has shown potential in VEXAS syndrome but data remain limited. This multicenter retrospective study assessed AZA efficacy and safety in 88 patients with genetically confirmed VEXAS syndrome from FRENVEX (French VEXAS study group), 80% meeting World Health Organization 2022 MDS criteria. Inflammatory response rates were 41% at 6 months and 54% at 12 months, regardless of MDS status. A total of 50 (61%) patients achieved inflammatory response, with 70% occurring at 6 months, suggesting a delayed median response. Among responders, relapse-free survival on AZA was 90% at 1 year and 85% at 5 years. Of the 12 responders who discontinued AZA, 9 relapsed after a median of 3.1 years (range, 0.4-5.6), with effective reexposure in 4 of 5 patients. Hematological responses included red blood cell transfusion independence in 65% and platelet improvement in 77% of patients. Molecular response, defined as a ≥25% reduction in UBA1 variant allele frequency (VAF), was observed in 65% of patients, all of whom achieved inflammatory and hematological responses; and VAF dropped to <2% in 43% of cases. Infections (34%) and cytopenias (36%) were common, particularly during the first 3 cycles. This study establishes AZA as an effective therapy for VEXAS syndrome, improving inflammation, cytopenias, and UBA1 clonal burden, warranting larger prospective trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antimetabolites, AntineoplasticAzacitidineMyelodysplastic SyndromesSkin Diseases, GeneticAdolescentAdultAgedChildChild, PreschoolFemaleHumansMaleMiddle AgedYoung AdultRetrospective StudiesTreatment OutcomeUbiquitin-Activating Enzymes

Substanzen

Antimetabolites, AntineoplasticAzacitidineUBA1 protein, humanUbiquitin-Activating Enzymes

Autor:innen und Institutionen

  • Service de Médecine Interne, Hôpital Saint-Antoine, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.
  • Service d'Hématologie Biologique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe Pharmacoépidémiologie et Évaluation des Soins, Hôpital Pitié-Salpétrière, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.
  • Service Hématologie Seniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.
  • Service de Médecine Interne, CHU Estaing, Clermont-Ferrand, France.
  • Service de Médecine Interne et Polyvalente, Centre Hospitalier du Haut-Anjou, Château-Gontier, France.

ORCID-Profile: Olivier Kosmider, Maxime Beydon, Lin-Pierre Zhao, Vincent Grobost, Guillaume Le Guenno, Yann Nguyen, Jérémie Dion, Maël Heiblig, Sylvain Thépot, Benoît Faucher, Antoine Néel, Roderau Outh, Holy Bezanahary, Julien Rossignol, Audrey Bidet, Guilaine Boursier, Benjamin Lebecque, Yannick Le Bris, Pierre Sujobert, Cédric Pastoret, David Rizzo, Nathalie Boiret-Dupré, Stéphanie Dulucq, Cassandra Jadeau, Jean-Baptiste Rieu, Sophie Georgin-Lavialle, Lucie Rigolot, Lise Larcher, Arsène Mékinian, Thibault Comont

Zitieren

APA

Jachiet, V., Kosmider, O., Beydon, M., Hadjadj, J., Zhao, L. P., Grobost, V., Lacombe, V., Le Guenno, G., Nguyen, Y., Arlet, J. B., Dion, J., Heiblig, M., Garnier, A., Samson, M., Aouba, A., Thépot, S., Dimicoli-Salazar, S., Dutasta, F., Faucher, B., …, & Comont, T. (2025). Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX. Blood, 146(12), 1450-1461. https://doi.org/10.1182/blood.2024028133

Vancouver

Jachiet V, Kosmider O, Beydon M, Hadjadj J, Zhao LP, Grobost V, et al. Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX. Blood. 2025;146(12):1450-1461. doi:10.1182/blood.2024028133

BibTeX
@article{Jachiet2025,
  author = {Jachiet, Vincent and Kosmider, Olivier and Beydon, Maxime and Hadjadj, Jérôme and Zhao, Lin-Pierre and Grobost, Vincent and Lacombe, Valentin and Le Guenno, Guillaume and Nguyen, Yann and Arlet, Jean-Benoît and Dion, Jérémie and Heiblig, Maël and Garnier, Alice and Samson, Maxime and Aouba, Achille and Thépot, Sylvain and Dimicoli-Salazar, Sophie and Dutasta, Fabien and Faucher, Benoît and Lazaro, Estibaliz and Morel, Véronique and Néel, Antoine and Outh, Roderau and Bezanahary, Holy and Rossignol, Julien and Alary, Anne-Sophie and Bidet, Audrey and Blateau, Pauline and Bouvier, Anne and Boursier, Guilaine and Decamp, Matthieu and Lebecque, Benjamin and Le Bris, Yannick and Sujobert, Pierre and Marceau-Renaut, Alice and Pastoret, Cédric and Rizzo, David and Boiret-Dupré, Nathalie and Boucher, Lara and Dulucq, Stéphanie and Genevieve, Franck and Jadeau, Cassandra and Lemaire, Pierre and Vazquez, Romain and Rieu, Jean-Baptiste and Fain, Olivier and Georgin-Lavialle, Sophie and Rigolot, Lucie and Larcher, Lise and Hirsch, Pierre and Terrier, Benjamin and Fenaux, Pierre and Mékinian, Arsène and Comont, Thibault},
  title = {Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX},
  journal = {Blood},
  year = {2025},
  volume = {146},
  number = {12},
  pages = {1450--1461},
  doi = {10.1182/blood.2024028133}
}
Kostenlos starten →